JDD October 2023 Issue Highlights | Special Topic: Atopic Dermatitis
182121821218212
The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen pl …
The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen pl … Continue reading "JDD October 2023 Issue Highlights | Special Topic: Atopic Dermatitis"
Dermatologists are prescribing oral glucocorticoids for psoriasis despite awareness of risks of life-threatening generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). A recent survey of dermatologists published in the Journal of Drugs in Dermatology found 18% of respondents occasionally prescribe oral glucocorticoids to patients with psoriasis, typically 1-5% of the time. Those wh … 
Biologics have revolutionized the treatment of psoriasis, and with new entries into the class, PASI90 and 100 have become attainable for many patients. In this installment of our Therapeutic Cheat Sheet series, we’ll cover everything you need to know to start and monitor your patients on IL-17 blocking therapies.
[caption id="attachment_8301" align="alignleft" width="612"] Click image to en … 